Bevenopran (CB-5945) (Synonyms: CB-5945; ADL-5945) |
カタログ番号GC30639 |
ベベノプラン (CB-5945) は、周辺の μ-オピオイド受容体アンタゴニストです。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 676500-67-7
Sample solution is provided at 25 µL, 10mM.
Bevenopran is a peripheral μ-opioid receptor antagonist.
Bevenopran is a peripheral μ-opioid receptor antagonist. Bevenopran is currently under investigation for the treatment of opioid-induced bowel dysfunction (OBD)[1]. Bevenopran tends to increase bowel movement (BM) frequency, especially for 0.1 mg twice daily and 4 mg daily, respectively[1].
[1]. Diego L, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56. [2]. Siemens W, et al. Advances in pharmacotherapy for opioid-induced constipation - a systematic review. Expert Opin Pharmacother. 2015 Mar;16(4):515-32.
Average Rating: 5
(Based on Reviews and 18 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *